www.heavensgatel2.fora.pl

[nlwxpearo]

Xenova's anti-addiction drug development


Surgery, this technology include bio-engineering methods used to create a human antibody,[link widoczny dla zalogowanych], this antibody expression is overexpressed in solid tumors,[link widoczny dla zalogowanych], the tumor antigen epitopes, especially here,[link widoczny dla zalogowanych], Tie a 22 and CD55. Immunization Vaccine Targeting dendritic cells to activate the body's immune effective. Scrip2004 (2956) 10 (Yu Miao Abstract) 09079Xenova the company's anti-addiction drug development in the addiction treatment field, it has two therapeutic vaccine currently in clinical evaluation, respectively, for cocaine and nicotine addiction. TA-CD is designed to induce antibodies cocaine ~ exclusive. Combination of cocaine in their blood to prevent them from being brain uptake, and then change the physiological response of people on the anesthetic, weakening it and break the addiction and enhance the nature of the abuse cycle. Ⅱ a clinical trial has demonstrated its positive results. TA-NIC is a combination of protein by a nicotine derivative coupled with recombinant cholera toxin B is made, the role of TA-CD with the same mechanism. In October 2003 I started a second clinical trial, plans to enter the 4th quarter of this year Ⅱ / Ⅲ clinical trial of this treatment for nicotine addiction vaccine efficacy studies. In addition, the company also has an immune treatment plan,[link widoczny dla zalogowanych], using a variety of technology development 0X4O/OX40I platform for cancer and autoimmune disease product candidate. Xenova company has reached an agreement Genentech Development Corporation and Celltech OX40 signaling pathway by decreasing the treatment of autoimmune diseases of the products, but retained on the cell surface proteins by upregulating for the treatment of cancer and infectious diseases, the right products. MktI2004, 31 (2 19 (Ming Zhang Abstract) 09080Pieris test Anticalin therapeutic proteins German company private biopharmaceutical company PierisProte-olab is developing a series of engineered proteins, these proteins are believed to substitute in the field of cancer and certain cardiovascular diseases antibody. In the next year the company hopes will be its first product into clinical trials. The company is committed to Anticalins development. Anticalin produced by biological engineering from the lipocalin antibodies with similar ligand binding function of proteins. Lipocalin protein is present in human tissues or body fluids of a group of strong (robust) protein. Technology companies use Anticalin limited disease targets for rapid production of high affinity human candidate protein. Them through its own R & D and with pharmaceutical companies, biotechnology companies and genomics companies to conduct R & D cooperation agreements. Clinical trials will involve one of its major development projects Digical. Earlier this year a pre-clinical studies can be found in this Anticalin and cardiac steroids in the digoxin caused a fatal overdose toxicity. Company said, Digical dose just a listing for the same indication had polyclonal antibody fragment product half the recommended dose. The researchers said the market there are three similar antibodies, respectively, from Protherics, GlaxoSmithKline and Roche company. Anticalin antibody has the advantage of them than smaller, more simply, from 160 to 180 with amino acid residues of a single polypeptide chain composition, specific higher doses and also less toxic, while more stable and cheaper. The researchers believe that the antagonism of this drug may be applicable to the mode for more indications. Scrip2004 (2955) 10 (Wang Luan Abstract) 09081MDX a promising II, 060 U.S. Medarex, reported the results of its fully human antibody targeting CD30 MDX a 060 (I) have a future phase Ⅱ clinical trial data. Early research included a multi-dose Phase I trial of two high doses of expansion unit involving 27 patients with refractory Hodgkin's disease,[link widoczny dla zalogowanych], developmental regression, or other large-cell lymphoma patients with CD30-positive lymphomas, including 85 patients 31 *